Rapport Therapeutics (NASDAQ:RAPP) Director James Healy Buys 44,032 Shares

Rapport Therapeutics (NASDAQ:RAPP) Director James Healy bought 44,032 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were acquired at an average cost of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the transaction, the director now owns 40,851 shares of the company’s stock, valued at approximately $1,001,666.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rapport Therapeutics Price Performance

Shares of RAPP opened at $23.30 on Friday. Rapport Therapeutics has a one year low of $18.00 and a one year high of $27.11.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Jefferies Financial Group began coverage on Rapport Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $35.00 target price for the company. TD Cowen began coverage on shares of Rapport Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock. Finally, Stifel Nicolaus began coverage on Rapport Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 target price for the company.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.